A5044929335- Melanoma and MAPK Pathways
- Advanced Breast Cancer Therapies
- Cancer Immunotherapy and Biomarkers
- Cutaneous Melanoma Detection and Management
- Nonmelanoma Skin Cancer Studies
- CAR-T cell therapy research
- Neurofibromatosis and Schwannoma Cases
- Cutaneous lymphoproliferative disorders research
- Cancer and Skin Lesions
- Immunotherapy and Immune Responses
- Neuroblastoma Research and Treatments
- Autoimmune Bullous Skin Diseases
- Genetic and rare skin diseases.
- Nail Diseases and Treatments
- Cancer Mechanisms and Therapy
- Colorectal Cancer Treatments and Studies
- Cancer Diagnosis and Treatment
- Synthesis and biological activity
- Genital Health and Disease
- Skin and Cellular Biology Research
- Infectious Diseases and Mycology
- Hedgehog Signaling Pathway Studies
- Soft tissue tumors and treatment
- Oral Health Pathology and Treatment
- Glioma Diagnosis and Treatment
Centre Léon Bérard
2021-2025
Hospices Civils de Lyon
2012-2024
Université Claude Bernard Lyon 1
2012-2024
Hôpital Lyon Sud
2012-2024
Centre de Recherche en Cancérologie de Lyon
2017-2024
Inserm
2017-2021
Centre National de la Recherche Scientifique
2017
Lyon College
2015
Advanced Dermatology
2013
Hôtel-Dieu de Lyon
2006
Vogt-Koyanagi-Harada (VKH) syndrome is a rare condition implicating systemic immune reaction against melanocytes. The pathophysiology unclear. A genetic predisposition has been suggested as HLA-DR4/DRB1*04 more common among VKH patients. Drug induced reported in advanced melanoma patients receiving immunotherapy, including ipilimumab and adoptive cell transfer of Tumor-Infiltrating Lymphocyte associated with IL-2. To date, no case anti PD-1 -induced described. We report here the patient...
The objective was to assess the response rate and survival of patients with metastatic mucosal melanoma (MM) uveal (UM) treated anti-CTLA-4 or anti-PD-1 monoclonal antibodies (mAbs). A multicenter retrospective study performed in 25 dermatology departments France. All stage III-C IV MM UM who were mAbs between 2008 2016 included compared after adjustment for main prognostic factors a second cohort chemotherapy. Tumor evaluated according RECIST v. 1.1 criteria at Week 12....
Melanoma treatment has been revolutionized with the development of immune-based therapies that offer durable clinical responses in a subset patients. Clinical outcomes after by immunotherapy can be influenced host's immune system. The system is modified age age-related dysfunction.To evaluate if influences outcome and adverse events patients treated for metastatic melanoma.This was single-center cohort analysis melanoma between January 2007 February 2016, Lyon Sud Hospital, France. A total...
Cutaneous adverse events (AEs) are the most prevalent toxicity under checkpoint inhibitors in clinical trials. In 'real-life' conditions of use, skin toxicities anti-PD-1 have not been described to date a large cohort. The objective this study was determine features patients with advanced melanoma receiving therapy use. Secondary objectives were evaluate characteristics and analyse associated extra-cutaneous toxicities, progression-free survival (PFS) overall (OS).Advanced treated nivolumab...
Anti-PD-1 and BRAF-inhibitors (BRAFi) have been approved as first-line treatments in advanced melanoma. To date, no prospective data are available to give the best sequence of treatment. The objective this study was evaluate real-life efficacy anti-PD-1 after BRAFi, ipilimumab, or chemotherapy failure. This a single institution cohort analysis patients treated with right Melanoma evolution initiation analyzed BRAF-mutated BRAF wild-type patients. treatment evaluated by Objective Response...
The need for reliable biomarkers to predict clinical benefit from anti-PD1 treatment in metastatic melanoma (MM) patients remains unmet. Several parameters have been considered the tumor environment or blood, but none has yet achieved sufficient accuracy routine practice. Whole blood samples MM receiving second-line (NCT02626065), collected longitudinally, were analyzed by flow cytometry assess immune cell subsets absolute numbers, expression of checkpoints ligands on T cells and...
Abstract BRAF and MEKis have revolutionized the management of V600 ‐mutated melanoma patients. Left ventricular ejection fraction decrease (LVEF‐D) related to these treatments has not been thoroughly evaluated date. The main objective this study was describe characteristics LVEF‐D in patients treated with and/or MEKis. Metastatic between March 1, 2012 May 18, 2018 were included retrospectively (Lyon Sud University Hospital, Hospices Civils de Lyon). defined as a reduction LVEF ≥10% from...
<i>Background:</i> Scleromyxedema is an unusual skin disease characterized by mucinous infiltration of the skin. There no satisfactory treatment for this disorder. <i>Case Report:</i> We report 2 cases scleromyxedema, both associated with IgG-λ paraprotein. Treatment thalidomide was started and great improvement lesion noted as shown a quality life questionnaire similar to those used in rheumatoid arthritis. TNF-α value elevated during treatment....
Abstract Background Dermoscopy is acknowledged to improve the diagnostic accuracy of melanoma by several concordant meta‐analyses. However, use dermoscopy was not considered as a high level evidence tool F rench Health Authorities. shown in A ustralian, merican and our recent surveys, used most dermatologists private practice. Objectives To analyse use, beliefs, teaching given research produced dermatology departments hospitals. Methods questionnaire about available equipment, activities...
<h3>Importance</h3> Since 2011, many patients with metastatic melanoma have been treated ipilimumab therapy and developed severe immune-related adverse events (AEs). Because several immune therapies are now available to treat melanoma, a better knowledge of mechanisms recurrence risks AEs is needed before reintroduction immunotherapies. <h3>Objectives</h3> To evaluate the risk toxic effects associated anti–programmed cell death 1 antibody (anti–PD-1) after discontinuation monotherapy because...
In BRAFV600MUT metastatic melanoma, cyclin D-CDK4/6-INK4-Rb pathway alterations are involved in resistance to MAPK inhibitors, suggesting a clinical benefit of cyclin-dependent kinase 4 (CDK4) inhibitors. this phase I-II study, we aimed establish the MTD palbociclib when added vemurafenib.Patients with BRAFV600E/KMUT melanoma harboring CDKN2A loss and RB1 expression were included stratified into two groups according previous BRAF inhibitor treatment (no:strata 1; yes:strata 2). Treatment...
Subungual squamous cell carcinoma (SU-SCC) is the most common malignant tumour of nail unit. Intraoperative dermoscopy has been described only for pigmented tumours, onychomatricoma and glomus tumours.To establish a description intraoperative dermoscopic features SU-SCC.A single-centre retrospective cohort 53 SU-SCC cases over 5-year period was reviewed by six examiners who individually scored 31 as present or absent. For each feature, frequency interobserver agreement evaluated, then data...